- Conditions
- Hepatitis C, Chronic
- Interventions
- Patients receiving Sof/Vel (Epclusa) and Navigation services
- Drug
- Lead sponsor
- San Francisco Department of Public Health
- Government
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- San Francisco, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 457–480
of 2,795
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Lung Cancer, Non-Small Cell Lung Cancer
- Interventions
- MPDL3280A, Carboplatin, Paclitaxel, Radiation Therapy
- Drug · Radiation
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2028
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Chronic Graft-versus-host-disease
- Interventions
- Axatilimab, Ruxolitinib, Corticosteroids
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 25
- States / cities
- Phoenix, Arizona • Duarte, California • Los Angeles, California + 18 more
- Conditions
- Breast Cancer
- Interventions
- multiple beams utilizing either intensity-modulated or 3D-conformal techniques
- Radiation
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 110 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2027
- U.S. locations
- 8
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 5 more
- Conditions
- Urinary Bladder Neoplasm
- Interventions
- Mitomycin C
- Drug
- Lead sponsor
- The University of Texas Health Science Center at San Antonio
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Cancer
- Interventions
- TJ004309, Atezolizumab
- Drug
- Lead sponsor
- I-Mab Biopharma US Limited
- Industry
- Eligibility
- Not listed
- U.S. locations
- 3
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- olodaterol, tiotropium, placebo
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 809 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 20
- States / cities
- Jasper, Alabama • Stamford, Connecticut • Clearwater, Florida + 17 more
- Conditions
- Hepatocellular Carcinoma, Hepatocellular Cancer, Hepatitis B, Cirrhosis, Liver Cancer
- Interventions
- Study CT/MRI Imaging, Standard of Care CT/MRI Imaging, Oncoguard™ Liver Test
- Device · Diagnostic Test
- Lead sponsor
- Exact Sciences Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,990 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 76
- States / cities
- Chandler, Arizona • Sun City, Arizona • Bakersfield, California + 62 more
- Conditions
- Urinary Tract Infections, Stress Urinary Incontinence, Urinary Incontinence
- Interventions
- Bactrim (800/160 mg), Keflex (500 mg), Cipro (250 mg), or Macrobid (100mg)
- Drug
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 2
- States / cities
- Miami, Florida
- Conditions
- COVID-19, Infectious Disease, Symptomatic COVID-19 Infection Laboratory-Confirmed, SARS CoV 2 Infection
- Interventions
- RQ-001, Placebo
- Combination Product · Other
- Lead sponsor
- Red Queen Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 6
- States / cities
- Los Angeles, California • Miami, Florida • Baltimore, Maryland + 3 more
- Conditions
- Portopulmonary Hypertension, Pulmonary Hypertension, Cirrhosis, Liver
- Interventions
- Ambrisentan Pill, Tadalafil Pill
- Drug
- Lead sponsor
- Ochsner Health System
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- New Orleans, Louisiana
- Conditions
- Childhood Atypical Teratoid/Rhabdoid Tumor, Childhood Central Nervous System Choriocarcinoma, Childhood Central Nervous System Germinoma, Childhood Central Nervous System Mixed Germ Cell Tumor, Childhood Central Nervous System Teratoma, Childhood Central Nervous System Yolk Sac Tumor, Childhood Choroid Plexus Tumor, Childhood Craniopharyngioma, Childhood Ependymoblastoma, Childhood Grade I Meningioma, Childhood Grade II Meningioma, Childhood Grade III Meningioma, Childhood Infratentorial Ependymoma, Childhood Medulloepithelioma, Childhood Mixed Glioma, Childhood Oligodendroglioma, Childhood Supratentorial Ependymoma, Gonadotroph Adenoma, Pituitary Basophilic Adenoma, Pituitary Chromophobe Adenoma, Pituitary Eosinophilic Adenoma, Prolactin Secreting Adenoma, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Anaplastic Large Cell Lymphoma, Recurrent Childhood Brain Stem Glioma, Recurrent Childhood Central Nervous System Embryonal Tumor, Recurrent Childhood Cerebellar Astrocytoma, Recurrent Childhood Cerebral Astrocytoma, Recurrent Childhood Ependymoma, Recurrent Childhood Grade III Lymphomatoid Granulomatosis, Recurrent Childhood Large Cell Lymphoma, Recurrent Childhood Lymphoblastic Lymphoma, Recurrent Childhood Medulloblastoma, Recurrent Childhood Pineoblastoma, Recurrent Childhood Small Noncleaved Cell Lymphoma, Recurrent Childhood Spinal Cord Neoplasm, Recurrent Childhood Subependymal Giant Cell Astrocytoma, Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor, Recurrent Childhood Visual Pathway and Hypothalamic Glioma, Recurrent Childhood Visual Pathway Glioma, Recurrent Pituitary Tumor, Recurrent/Refractory Childhood Hodgkin Lymphoma, T-cell Childhood Acute Lymphoblastic Leukemia, T-cell Large Granular Lymphocyte Leukemia, TSH Secreting Adenoma, Unspecified Childhood Solid Tumor, Protocol Specific
- Interventions
- gamma-secretase/Notch signalling pathway inhibitor RO4929097, diagnostic laboratory biomarker analysis, pharmacological study, dexamethasone
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 1 Year to 21 Years
- Enrollment
- 129 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 11
- States / cities
- Palo Alto, California • Stanford, California • Chicago, Illinois + 8 more
- Conditions
- Cystic Fibrosis, Lung Transplant; Complications
- Interventions
- Clinical Tool (Mobile Spirometry and Survey)
- Other
- Lead sponsor
- The Cleveland Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Osteopenia
- Interventions
- Time-restricted eating combined with resistance exercise (TRE+Ex), Habitual eating pattern combined with resistance exercise (HE+Ex)
- Behavioral
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 50 Years to 75 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Asthma
- Interventions
- Budesonide/albuterol sulfate metered-dose inhaler 160/180 μg, Budesonide/albuterol sulfate metered-dose inhaler 80/180 μg, Albuterol sulfate metered-dose inhaler 180 μg
- Combination Product · Drug
- Lead sponsor
- Bond Avillion 2 Development LP
- Industry
- Eligibility
- 4 Years and older
- Enrollment
- 3,132 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 170
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 139 more
- Conditions
- Tobacco-Related Carcinoma
- Interventions
- Health communications
- Other
- Lead sponsor
- Ohio State University Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years to 35 Years
- Enrollment
- 2,849 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Bladder Cancer
- Interventions
- Cisplatin, Gemcitabine, Bevacizumab
- Drug
- Lead sponsor
- Christopher Sweeney, MBBS
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 11
- States / cities
- Chicago, Illinois • Galesburg, Illinois • Evansville, Indiana + 7 more
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Venetoclax, Gemtuzumab, Ziftomenib
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 3 Years to 21 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- HIV-1-infection
- Interventions
- GS-3242 Tablet, GS-3242 Injection, Lenacapavir Tablet, Lenacapavir Injection, B/F/TAF
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 700 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2033
- U.S. locations
- 15
- States / cities
- Torrance, California • New Haven, Connecticut • Ft. Pierce, Florida + 11 more
- Conditions
- Cancer-related Fatigue, Breast Cancer, Prostate Cancer
- Interventions
- Telehealth Exercise Program
- Behavioral
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years to 89 Years
- Enrollment
- 134 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 2
- States / cities
- Aurora, Colorado • Missoula, Montana
- Conditions
- Endometriosis Related Pain
- Interventions
- Relugolix, Estradiol/norethindrone acetate, Estradiol/norethindrone acetate placebo, Relugolix placebo
- Drug
- Lead sponsor
- Myovant Sciences GmbH
- Industry
- Eligibility
- 18 Years to 50 Years · Female only
- Enrollment
- 623 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 41
- States / cities
- Andalusia, Alabama • Washington D.C., District of Columbia • Aventura, Florida + 36 more
- Conditions
- Advanced Pancreatic Adenocarcinoma, Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
- Interventions
- Educational Intervention, Quality-of-Life Assessment, Questionnaire Administration, Resistance Training
- Other
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2026
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Extensive-stage Small-cell Lung Cancer
- Interventions
- Durvalumab 50 MG/1 ML Intravenous Solution, Etoposide Injection, Cisplatin, Carboplatin, Stereotactic Body Radiotherapy
- Drug · Device
- Lead sponsor
- University of Maryland, Baltimore
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027 – 2028
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Rectal Cancer
- Interventions
- Capecitabine, Irinotecan, EUS, Neoadjuvant Chemotherapy, Preoperative Radiation, Surgery, Adjuvant Chemotherapy
- Drug · Procedure
- Lead sponsor
- Gabi Chiorean, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 9
- States / cities
- Elkhart, Indiana • Fort Wayne, Indiana • Goshen, Indiana + 5 more